Annexon, Inc.
annexonbio.comWhat Do They Do?
Develops experimental medicines that block part of the immune system to treat inflammatory diseases affecting the body, brain and eyes.
10-K for FY2025, filed Mar 30, 2026
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 30, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 12, 2026
−$55.3MView ↗
- ▲ +13% (Loss)
- vs −$49.2M in Q2 FY2025
Pipeline focus
The earlier report presented GBS, Huntington’s disease, geographic atrophy and lupus nephritis among its flagship programs; the latest prioritizes late-stage work in GBS and geographic atrophy, while continuing development of an oral small molecule for autoimmune conditions.
10-K for FY2022, filed Mar 6, 2023 10-K for FY2025, filed Mar 30, 2026Guillain-Barré Syndrome, or GBS: We are advancing our lead candidate, ANX005, an investigational, full-length monoclonal antibody, or mAb…View ↗
Huntington’s Disease, or HD: We are evaluating ANX005 for the potential treatment of patients with HD, a slowly progressing, inherited and…View ↗
Geographic Atrophy, or GA: We are evaluating ANX007, an antigen-binding fragment, or Fab, formulated for intravitreal administration, for…View ↗
Lupus Nephritis, or LN: We are advancing a Phase 1b signal-finding trial of ANX009, a C1q Fab formulated for subcutaneous delivery, using a…View ↗
Who Do They Compete With?
Competes with Hansa Biopharma, AstraZeneca, Alexion, argenx, Apellis, Astellas, Regeneron, Aviceda Therapeutics, Janssen, Novartis, Perceive Bio, Roche, Alkeus, Belite Bio, Stealth BioTherapeutics, Boehringer Ingelheim, Galimedix Therapeutics, Cognition Therapeutics, ONL Therapeutics, and Ocugen
10-K for FY2025, filed Mar 30, 2026There are currently no approved therapies for GBS in the United States. IVIg and PE are the most commonly used therapies in the Western…View ↗
Loading...
